Questioning the Value of Subcutaneous Pembrolizumab

A new commentary published in the Journal of Clinical Oncology questions whether the subcutaneous formulation of the immunotherapy drug pembrolizumab provides genuine value to patients and health systems or if its primary benefit is merely convenience.

The piece, authored by Laure-Anne Teuwen, Rachel P. Riechelmann, and Bishal Gyawali, an Associate Professor at Queen’s University, examines the implications of shifting from intravenous to subcutaneous administration of the drug.

While the subcutaneous version is marketed as a more efficient alternative, the authors argue that the approval of this formulation raises broader questions regarding how the medical community defines meaningful innovation in cancer care.

Convenience and Administration Efficiency

The primary arguments in favor of the subcutaneous formulation center on improved convenience and efficiency for both the healthcare system and the patient.

Proponents suggest that this method of delivery allows for more flexible administration settings, potentially moving the process outside of traditional infusion centers.

Clinical data from the KEYNOTE-D77 study indicated non-inferior pharmacokinetics compared to the intravenous version, and the subcutaneous route is noted for reducing chair time for patients during treatment.

Concerns Over Patent Hopping and Cost

Despite these efficiency gains, Gyawali and his colleagues question the actual cost of this convenience to health systems.

In our opinion, What we have is simply a case of patent hopping which is expensive to health systems and thwarts efforts at dose optimization of immunotherapies.

Bishal Gyawali

The authors suggest that such strategies may be designed to extend patent protections rather than to provide a significant clinical leap in patient outcomes.

This critique builds upon previous research conducted by Gyawali regarding the cost of convenience within cancer care, suggesting that the financial burden on health systems may outweigh the perceived benefits of a faster administration process.

Impact on Dose Optimization

Beyond the financial implications, the commentary highlights a potential scientific drawback regarding the development of immunotherapies.

The authors argue that prioritizing a new delivery formulation over the optimization of the drug’s dose could hinder efforts to refine how these therapies are used to treat patients.

By focusing on the method of delivery, the authors suggest that the industry may be diverting attention from the more critical goal of determining the most effective dose for maximum therapeutic impact.